{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:19:42Z","timestamp":1787314782101,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC 2145 SyNergy \u2013 ID 390857198"],"award-info":[{"award-number":["EXC 2145 SyNergy \u2013 ID 390857198"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Metabolic network analysis of FDG-PET utilizes an index of inter-regional correlation of resting state glucose metabolism and has been proven to provide complementary information regarding the disease process in parkinsonian syndromes. The goals of this study were (i) to evaluate pattern similarities of glucose metabolism and network connectivity in dementia with Lewy bodies (DLB) subjects with subthreshold dopaminergic loss compared to advanced disease stages and to (ii) investigate metabolic network alterations of FDG-PET for discrimination of patients with early DLB from other neurodegenerative disorders (Alzheimer\u2019s disease, Parkinson\u2019s disease, multiple system atrophy) at individual patient level via principal component analysis (PCA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      FDG-PETs of subjects with probable or possible DLB (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200922) without significant dopamine deficiency (\n                      <jats:italic>z<\/jats:italic>\n                      -score\u2009&lt;\u20092 in putamen binding loss on DaT-SPECT compared to healthy controls (HC)) were scaled by global-mean, prior to volume-of-interest-based analyses of relative glucose metabolism. Single region metabolic changes and network connectivity changes were compared against HC (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200923) and against DLB subjects with significant dopamine deficiency (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200986). PCA was applied to test discrimination of patients with DLB from disease controls (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009101) at individual patient level.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Similar patterns of hypo- (parietal- and occipital cortex) and hypermetabolism (basal ganglia, limbic system, motor cortices) were observed in DLB patients with and without significant dopamine deficiency when compared to HC. Metabolic connectivity alterations correlated between DLB patients with and without significant dopamine deficiency (\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.597,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). A PCA trained by DLB patients with dopamine deficiency and HC discriminated DLB patients without significant dopaminergic loss from other neurodegenerative parkinsonian disorders at individual patient level (area-under-the-curve (AUC): 0.912).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Disease-specific patterns of altered glucose metabolism and altered metabolic networks are present in DLB subjects without significant dopaminergic loss. Metabolic network alterations in FDG-PET can act as a supporting biomarker in the subgroup of DLB patients without significant dopaminergic loss at symptoms onset.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-023-06493-w","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T03:02:30Z","timestamp":1700103750000},"page":"1023-1034","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Metabolic network alterations as a supportive biomarker in dementia with Lewy bodies with preserved dopamine transmission"],"prefix":"10.1007","volume":"51","author":[{"given":"Anna","family":"Stockbauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Kreuzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Palleis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Katzdobler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris-Stephan","family":"Rauchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Morbelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Chincarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Bruffaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica G.","family":"Kramberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Trost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Garibotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Nicastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Lathuili\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afina W.","family":"Lemstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart N. M.","family":"van Berckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pilotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Padovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Ochoa-Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Davidsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valle","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Peira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bauckneht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmario","family":"Sambuceti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"Aarsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Nobili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattes","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"V\u00f6glein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Perneczky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Pogarell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Buerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai","family":"Franzmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Danek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter U.","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bartenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cumming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Rominger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9247-2843","authenticated-orcid":false,"given":"Matthias","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"issue":"23","key":"6493_CR1","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1212\/01.wnl.0000436942.55281.47","volume":"81","author":"TJ Ferman","year":"2013","unstructured":"Ferman TJ, et al. Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology. 2013;81(23):2032\u20138.","journal-title":"Neurology"},{"issue":"14","key":"6493_CR2","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1017\/S0033291717003956","volume":"48","author":"PC Donaghy","year":"2018","unstructured":"Donaghy PC, et al. Neuropsychiatric symptoms and cognitive profile in mild cognitive impairment with Lewy bodies. Psychol Med. 2018;48(14):2384\u201390.","journal-title":"Psychol Med"},{"issue":"10004","key":"6493_CR3","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(15)00462-6","volume":"386","author":"Z Walker","year":"2015","unstructured":"Walker Z, et al. Lewy body dementias. Lancet. 2015;386(10004):1683\u201397.","journal-title":"Lancet"},{"issue":"1","key":"6493_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88\u2013100.","journal-title":"Neurology"},{"issue":"2","key":"6493_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/WAD.0000000000000007","volume":"28","author":"JH Yoon","year":"2014","unstructured":"Yoon JH, et al. The mild cognitive impairment stage of dementia with Lewy bodies and Parkinson disease: a comparison of cognitive profiles. Alzheimer Dis Assoc Disord. 2014;28(2):151\u20135.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"4","key":"6493_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1001\/jamaneurol.2017.4243","volume":"75","author":"R Savica","year":"2018","unstructured":"Savica R, Boeve BF, Mielke MM. When do alpha-synucleinopathies start? An epidemiological timeline: a review. JAMA Neurol. 2018;75(4):503\u20139.","journal-title":"JAMA Neurol"},{"issue":"2","key":"6493_CR7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3233\/JAD-161089","volume":"58","author":"D Sadiq","year":"2017","unstructured":"Sadiq D, et al. Prodromal dementia with Lewy bodies and prodromal Alzheimer\u2019s disease: a comparison of the cognitive and clinical profiles. J Alzheimers Dis. 2017;58(2):463\u201370.","journal-title":"J Alzheimers Dis"},{"issue":"17","key":"6493_CR8","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","volume":"94","author":"IG McKeith","year":"2020","unstructured":"McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94(17):743\u201355. https:\/\/doi.org\/10.1212\/WNL.0000000000009323.","journal-title":"Neurology."},{"issue":"3","key":"6493_CR9","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1017\/S0033291718000995","volume":"49","author":"AJ Thomas","year":"2019","unstructured":"Thomas AJ, et al. Diagnostic accuracy of dopaminergic imaging in prodromal dementia with Lewy bodies. Psychol Med. 2019;49(3):396\u2013402.","journal-title":"Psychol Med"},{"key":"6493_CR10","doi-asserted-by":"crossref","unstructured":"McCleery J, et al. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies. Cochrane Database Syst Rev. 2015;1(1):CD010633.","DOI":"10.1002\/14651858.CD010633.pub2"},{"issue":"6","key":"6493_CR11","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1007\/s00259-016-3312-x","volume":"43","author":"JJ van der Zande","year":"2016","unstructured":"van der Zande JJ, et al. [(123)]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies. Eur J Nucl Med Mol Imaging. 2016;43(6):1060\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"6493_CR12","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1212\/WNL.0000000000004254","volume":"89","author":"AJ Thomas","year":"2017","unstructured":"Thomas AJ, et al. Author response: autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology. 2017;89(7):751.","journal-title":"Neurology"},{"key":"6493_CR13","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.neuroimage.2013.03.070","volume":"78","author":"M Niethammer","year":"2013","unstructured":"Niethammer M, et al. Parkinson\u2019s disease cognitive network correlates with caudate dopamine. Neuroimage. 2013;78:204\u20139.","journal-title":"Neuroimage"},{"issue":"2","key":"6493_CR14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1177\/0271678X16637880","volume":"37","author":"JH Ko","year":"2017","unstructured":"Ko JH, Lee CS, Eidelberg D. Metabolic network expression in parkinsonism: clinical and dopaminergic correlations. J Cereb Blood Flow Metab. 2017;37(2):683\u201393.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"7","key":"6493_CR15","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1089\/brain.2020.0988","volume":"11","author":"G Zorzi","year":"2021","unstructured":"Zorzi G, et al. Changes of metabolic connectivity in dementia with Lewy bodies with visual hallucinations: a (18)F-fluorodeoxyglucose positron emission tomography\/magnetic resonance study. Brain Connect. 2021;11(7):518\u201328.","journal-title":"Brain Connect"},{"key":"6493_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.neurobiolaging.2018.12.001","volume":"76","author":"F Massa","year":"2019","unstructured":"Massa F, et al. Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI. Neurobiol Aging. 2019;76:9\u201317.","journal-title":"Neurobiol Aging"},{"issue":"2","key":"6493_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/eb-2017-102848","volume":"21","author":"A Surendranathan","year":"2018","unstructured":"Surendranathan A, O\u2019Brien JT. Clinical imaging in dementia with Lewy bodies. Evid Based Ment Health. 2018;21(2):61\u20135.","journal-title":"Evid Based Ment Health"},{"issue":"4","key":"6493_CR18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/mds.27945","volume":"35","author":"M Huber","year":"2020","unstructured":"Huber M, et al. Metabolic correlates of dopaminergic loss in dementia with Lewy bodies. Mov Disord. 2020;35(4):595\u2013605.","journal-title":"Mov Disord"},{"key":"6493_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.930735","volume":"16","author":"C Boccalini","year":"2022","unstructured":"Boccalini C, et al. Metabolic connectivity of resting-state networks in alpha synucleinopathies, from prodromal to dementia phase. Front Neurosci. 2022;16: 930735.","journal-title":"Front Neurosci"},{"issue":"15","key":"6493_CR20","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.1002\/hbm.24719","volume":"40","author":"A Sala","year":"2019","unstructured":"Sala A, et al. Vulnerability of multiple large-scale brain networks in dementia with Lewy bodies. Hum Brain Mapp. 2019;40(15):4537\u201350.","journal-title":"Hum Brain Mapp"},{"key":"6493_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2022.103080","volume":"35","author":"M Perovnik","year":"2022","unstructured":"Perovnik M, et al. Metabolic brain pattern in dementia with Lewy bodies: relationship to Alzheimer\u2019s disease topography. Neuroimage Clin. 2022;35: 103080.","journal-title":"Neuroimage Clin"},{"issue":"5","key":"6493_CR22","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ana.25453","volume":"85","author":"S Morbelli","year":"2019","unstructured":"Morbelli S, et al. Metabolic patterns across core features in dementia with lewy bodies. Ann Neurol. 2019;85(5):715\u201325.","journal-title":"Ann Neurol"},{"issue":"7","key":"6493_CR23","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00259-015-3304-2","volume":"43","author":"NL Albert","year":"2016","unstructured":"Albert NL, et al. Implementation of the European multicentre database of healthy controls for [(123)I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. Eur J Nucl Med Mol Imaging. 2016;43(7):1315\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"6493_CR24","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/s00259-017-3832-z","volume":"44","author":"M Brendel","year":"2017","unstructured":"Brendel M, et al. Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET. Eur J Nucl Med Mol Imaging. 2017;44(13):2239\u201348.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"6493_CR25","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"6493_CR26","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614\u201329.","journal-title":"Lancet Neurol"},{"issue":"9","key":"6493_CR27","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman S, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670\u20136.","journal-title":"Neurology"},{"issue":"12","key":"6493_CR28","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30(12):1591\u2013601.","journal-title":"Mov Disord"},{"issue":"4","key":"6493_CR29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/hbm.10123","volume":"19","author":"A Hammers","year":"2003","unstructured":"Hammers A, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19(4):224\u201347.","journal-title":"Hum Brain Mapp"},{"issue":"5","key":"6493_CR30","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1002\/hbm.22295","volume":"35","author":"S Peng","year":"2014","unstructured":"Peng S, et al. Characterization of disease-related covariance topographies with SSMPCA toolbox: effects of spatial normalization and PET scanners. Hum Brain Mapp. 2014;35(5):1801\u201314.","journal-title":"Hum Brain Mapp"},{"issue":"1","key":"6493_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13195-019-0473-4","volume":"11","author":"SP Caminiti","year":"2019","unstructured":"Caminiti SP, et al. Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria. Alzheimers Res Ther. 2019;11(1):20.","journal-title":"Alzheimers Res Ther"},{"key":"6493_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2021.102754","volume":"31","author":"K Kantarci","year":"2021","unstructured":"Kantarci K, et al. FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. Neuroimage Clin. 2021;31: 102754.","journal-title":"Neuroimage Clin"},{"issue":"1","key":"6493_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41531-020-00141-y","volume":"6","author":"J Brumberg","year":"2020","unstructured":"Brumberg J, et al. Differential diagnosis of parkinsonism: a head-to-head comparison of FDG PET and MIBG scintigraphy. NPJ Parkinsons Dis. 2020;6(1):39.","journal-title":"NPJ Parkinsons Dis"},{"issue":"10","key":"6493_CR34","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.tins.2009.06.003","volume":"32","author":"D Eidelberg","year":"2009","unstructured":"Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci. 2009;32(10):548\u201357.","journal-title":"Trends Neurosci"},{"issue":"7","key":"6493_CR35","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1474-4422(18)30169-8","volume":"17","author":"KA Schindlbeck","year":"2018","unstructured":"Schindlbeck KA, Eidelberg D. Network imaging biomarkers: insights and clinical applications in Parkinson\u2019s disease. Lancet Neurol. 2018;17(7):629\u201340.","journal-title":"Lancet Neurol"},{"issue":"2","key":"6493_CR36","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00259-019-04570-7","volume":"47","author":"SK Meles","year":"2020","unstructured":"Meles SK, et al. Abnormal pattern of brain glucose metabolism in Parkinson\u2019s disease: replication in three European cohorts. Eur J Nucl Med Mol Imaging. 2020;47(2):437\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"6493_CR37","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.3233\/JPD-202117","volume":"10","author":"CC Tang","year":"2020","unstructured":"Tang CC, et al. Hemispheric network expression in Parkinson\u2019s disease: relationship to dopaminergic asymmetries. J Parkinsons Dis. 2020;10(4):1737\u201349.","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"6493_CR38","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00259-021-05483-0","volume":"49","author":"K Etminani","year":"2022","unstructured":"Etminani K, et al. A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer\u2019s disease, and mild cognitive impairment using brain 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2022;49(2):563\u201384.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Pt 2","key":"6493_CR39","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/brain\/awr327","volume":"135","author":"ER Kenny","year":"2012","unstructured":"Kenny ER, et al. Functional connectivity in cortical regions in dementia with Lewy bodies and Alzheimer\u2019s disease. Brain. 2012;135(Pt 2):569\u201381.","journal-title":"Brain"},{"key":"6493_CR40","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.nicl.2014.03.013","volume":"4","author":"LR Peraza","year":"2014","unstructured":"Peraza LR, et al. fMRI resting state networks and their association with cognitive fluctuations in dementia with Lewy bodies. Neuroimage Clin. 2014;4:558\u201365.","journal-title":"Neuroimage Clin"},{"key":"6493_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105288","volume":"108","author":"SP Caminiti","year":"2023","unstructured":"Caminiti SP, et al. Dopaminergic connectivity reconfiguration in the dementia with Lewy bodies continuum. Parkinsonism Relat Disord. 2023;108: 105288.","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"6493_CR42","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1007\/s00415-020-09790-8","volume":"267","author":"T Iizuka","year":"2020","unstructured":"Iizuka T, Kameyama M. Spatial metabolic profiles to discriminate dementia with Lewy bodies from Alzheimer disease. J Neurol. 2020;267(7):1960\u20139.","journal-title":"J Neurol"},{"issue":"1","key":"6493_CR43","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2967\/jnumed.111.096578","volume":"53","author":"NI Bohnen","year":"2012","unstructured":"Bohnen NI, et al. Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. J Nucl Med. 2012;53(1):59\u201371.","journal-title":"J Nucl Med"},{"issue":"4","key":"6493_CR44","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1007\/s00259-022-06069-0","volume":"50","author":"F Lanfranchi","year":"2023","unstructured":"Lanfranchi F, et al. Different z-score cut-offs for striatal binding ratio (SBR) of DaT SPECT are needed to support the diagnosis of Parkinson\u2019s disease (PD) and dementia with Lewy bodies (DLB). Eur J Nucl Med Mol Imaging. 2023;50(4):1090\u2013102.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"6493_CR45","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.2967\/jnumed.119.239418","volume":"61","author":"DD Maltais","year":"2020","unstructured":"Maltais DD, et al. Confirmation of (123)I-FP-CIT SPECT quantification methods in dementia with Lewy bodies and other neurodegenerative disorders. J Nucl Med. 2020;61(11):1628\u201335.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06493-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06493-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06493-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T04:04:32Z","timestamp":1708488272000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06493-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["6493"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06493-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]},"assertion":[{"value":"9 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (LMU Munich\u2014application numbers 17-569 and 399-09) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed written consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"L.B. is an Novartis Radiopharmaceuticals GmbH employee, unrelated to this work. M.B. received speaker honoraria from GE healthcare, Roche and LMI and is an advisor of LMI. OP received speaker fees from Lundbeck, Otsuka, Takeda and Janssen. R.P. has received honoraria for advisory boards and speaker engagements from Roche, EISAI, Eli Lilly, Biogen, Janssen-Cilag, Astra Zeneca, Schwabe, Grifols, Novo Nordisk and Tabuk. VG received financial support for research and\/or speaker fees through her institution from Siemens Healthineers, GE Healthcare and Novo Nordisk.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}